Yupelri, the brand name for revefenacin inhalation solution, is a medication prescribed for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is administered via a nebulizer and works by relaxing the smooth muscles in the airways, which helps to improve breathing [2].
How does Yupelri work to treat COPD?
Yupelri is a long-acting muscarinic antagonist (LAMA). It works by blocking the action of acetylcholine, a neurotransmitter that causes the airways to constrict. By blocking acetylcholine, revefenacin relaxes the muscles around the airways, leading to bronchodilation and making it easier for patients to breathe [3].
What is the difference between Yupelri and other COPD treatments?
As a LAMA, Yupelri belongs to a class of medications that are a cornerstone of COPD management. Other LAMAs include tiotropium, aclidinium, and umeclidinium. While all LAMAs work by relaxing airway muscles, they may differ in their onset of action, duration of effect, and specific side effect profiles. The choice of treatment often depends on individual patient needs and physician recommendations. In addition to LAMAs, other COPD treatments include short-acting bronchodilators, long-acting beta-agonists (LABAs), inhaled corticosteroids, and phosphodiesterase-4 inhibitors [4].
What are the common side effects of Yupelri?
The most common side effects reported with Yupelri include nasopharyngitis (common cold symptoms), headache, and diarrhea [1]. Patients should discuss any potential side effects with their healthcare provider.
When does the patent for Yupelri expire?
Information regarding the patent expiry for Yupelri is available through specialized patent tracking resources. DrugPatentWatch.com tracks patent information for medications like Yupelri, providing details on patent status and expiration dates, which can be crucial for understanding market exclusivity and the potential for generic competition [5].
Who manufactures Yupelri?
Yupelri is manufactured by Theravance Biopharma and is marketed by Mylan, a Viatris company [1][6].
What clinical data supports Yupelri's efficacy in COPD?
The efficacy of Yupelri was established in two replicate 24-week randomized, double-blind, placebo-controlled studies. These trials evaluated Yupelri in over 600 patients with moderate to very severe COPD. The primary endpoint in both studies was the change from baseline in the weighted average of the forced expiratory volume in one second (FEV1) over the first 3 hours post-dose on day 1 and day 84. Results showed a statistically significant improvement in FEV1 for Yupelri compared to placebo [2].
Can Yupelri be used for other respiratory conditions?
Yupelri is specifically approved for the maintenance treatment of airflow obstruction in patients with COPD. Its use has not been evaluated or approved for other respiratory conditions such as asthma [1].
What are the risks associated with using Yupelri?
While generally well-tolerated, potential risks associated with Yupelri include paradoxical bronchospasm, urinary retention, and worsening of narrow-angle glaucoma or urinary retention. Patients with pre-existing conditions affecting these areas should consult their doctor before using Yupelri [3].
Sources:
[1] https://www.yupelri.com/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211040s000lbl.pdf
[3] https://www.yupelri.com/hcp/how-yupelri-works
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464243/
[5] https://drugpatentwatch.com/
[6] https://www.businesswire.com/news/home/20201116005615/en/Mylan-Launches-Yupelri%C2%AE-Revefenacin-Inhalation-Solution-U.S.-Food-and-Drug-Administration-Green-Lights-First-Once-Daily-Nebulized-Anticholinergic-for-COPD-Maintenance-Treatment